Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant.
The project forms part of the company’s strategic plan to increase its development capacity and resources in North America. The expansion will see the construction of an additional laboratory space for development projects. The building, installation and validation of equipment is expected to be completed by Q1 2018.
The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new analytical laboratory and pilot plant with a total reactor capacity of 4000 liters are currently being completed.
“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand, and this in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, Vice President US Operations, Cambrex.
Cambrex’s Charles City, Iowa facility is located on a 18-hectare site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The High Point site, formerly PharmaCore, Inc., was acquired by Cambrex in October 2016, and produces complex APIs and intermediates in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.